Literature DB >> 30911077

HPV-negative tumors of the uterine cervix.

Inmaculada Nicolás1,2, Lorena Marimon2,3, Esther Barnadas2,3, Adela Saco3, Leonardo Rodríguez-Carunchio3, Pere Fusté1, Cristina Martí1, Adriano Rodriguez-Trujillo1, Aureli Torne1, Marta Del Pino1, Jaume Ordi4,5.   

Abstract

Human papillomaviruses (HPV) are the causative agents of virtually all cervical carcinomas. Nevertheless, a small proportion of cervical cancer are negative for HPV, although the significance of this finding remains unclear. We aimed to provide insight into the differential clinico-pathological characteristics of this unusual subset of HPV-negative cervical cancer. We performed HPV-DNA detection using a highly sensitive PCR test (SPF10) and p16 immunostaining in 214 cervical carcinomas specimens from women treated at the Gynecological Oncology Unit of the Hospital Clinic (Barcelona, Spain) from 2012 to 2015. The clinical and pathological characteristics, including disease-free survival and overall survival, of HPV-negative and -positive cervical carcinomas were compared. Twenty-one out of 214 tumors (10%) were negative for HPV DNA. HPV-negative tumors were more frequently of the non-squamous type (9/21, 43% vs. 37/193, 19%; p < 0.01) and showed negative p16 staining (9/21; 43% vs. 7/193; 4%; p < 0.01). HPV-negative tumors were more frequently diagnosed at advanced FIGO stage (19/21, 91% vs. 110/193, 57%; p < 0.01) and more frequently had lymph node metastases (14/21, 67% vs. 69/193, 36%; p < 0.01). Patients with HPV-negative cervical cancer had a significantly worse disease-free survival (59.8 months, 95% confidence interval 32.0-87.6 vs. 132.2 months, 95% confidence interval 118.6-145.8; p < 0.01) and overall survival (77.0 months, 95% confidence interval 47.2-106.8 vs. 153.8 months, 95% confidence interval 142.0-165.6; p = 0.01) than women with HPV-positive tumors. However, only advanced FIGO stage and lymph node metastases remained associated with a poor disease-free survival and overall survival on multivariate analysis. In conclusion, our results suggest that a low percentage of cervical cancer arise via an HPV-independent pathway. These HPV-negative tumors are diagnosed at advanced stages, show higher prevalence of lymph nodes metastases and have an impaired prognosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30911077     DOI: 10.1038/s41379-019-0249-1

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

Review 1.  The functions of lncRNAs in the HPV-negative cervical cancer compared with HPV-positive cervical cancer.

Authors:  Yi Liu; Hejing Liu; Bo Sheng; Shuya Pan; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Apoptosis       Date:  2022-08-18       Impact factor: 5.561

2.  LncRNA SOX2OT affects cervical cancer cell growth, migration and invasion by regulating SOX2.

Authors:  Xiaohan Chang; Huijie Zhang; Qing Yang; Li Pang
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

Review 3.  [Conventional grading vs. molecular grading : Decision aids for clinical routine].

Authors:  C Kakies; D Louise Dräger; P Spiess; O W Hakenberg; C Protzel
Journal:  Urologe A       Date:  2021-06-28       Impact factor: 0.639

4.  Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens.

Authors:  Paula Böttinger; Karin Schreiber; Elizabeth Hyjek; Thomas Krausz; Michael T Spiotto; Madeline Steiner; Christian Idel; Heather Booras; Gabriele Beck-Engeser; Jessie Riederer; Gerald Willimsky; Steven P Wolf; Theodore Karrison; Elizabeth Jensen; Ralph R Weichselbaum; Yusuke Nakamura; Poh Yin Yew; Paul F Lambert; Takeshi Kurita; Kazuma Kiyotani; Matthias Leisegang; Hans Schreiber
Journal:  Carcinogenesis       Date:  2020-11-13       Impact factor: 4.944

Review 5.  Progress in the pathological arena of gynecological cancers.

Authors:  W Glenn McCluggage
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

6.  LncRNA DCST1-AS1 Sponges miR-107 to Upregulate CDK6 in Cervical Squamous Cell Carcinoma.

Authors:  Zhigang Zhou; Na Xia
Journal:  Cancer Manag Res       Date:  2020-08-28       Impact factor: 3.989

Review 7.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 8.  HPV-Negative Cervical Cancer: A Narrative Review.

Authors:  Francesca Arezzo; Gennaro Cormio; Vera Loizzi; Gerardo Cazzato; Viviana Cataldo; Claudio Lombardi; Giuseppe Ingravallo; Leonardo Resta; Ettore Cicinelli
Journal:  Diagnostics (Basel)       Date:  2021-05-26

9.  Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer.

Authors:  Arjan Kol; Joyce M Lubbers; Anouk L J Terwindt; Hagma H Workel; Annechien Plat; G Bea A Wisman; Joost Bart; Hans W Nijman; Marco De Bruyn
Journal:  Oncoimmunology       Date:  2021-06-12       Impact factor: 8.110

10.  PD-1 Expression Status on CD8+ Tumour Infiltrating Lymphocytes Associates With Survival in Cervical Cancer.

Authors:  Peiwen Fan; Xi Li; Yaning Feng; Hongchao Cai; Danning Dong; Yanchun Peng; Xuan Yao; Yuping Guo; Miaomiao Ma; Tao Dong; Ruozheng Wang
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.